PFE logo Pfizer +
Pfizer
+

Pfizer (PFE) Business News

Track Pfizer in real time with a live news feed covering Pfizer stock news, official press releases, company announcements, and an archive of historical Pfizer news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
6:45 AM | Thursday | Jun 18, 2026 Business Wire

Pfizer Announces Chief Financial Officer Transition

NEW News Thumbnail
6:45 AM | Monday | Jun 8, 2026 Business Wire

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

News Thumbnail
9:00 AM | Saturday | Jun 6, 2026 Business Wire

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

News Thumbnail
10:00 AM | Monday | Jun 1, 2026 Business Wire

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

News Thumbnail
8:00 AM | Sunday | May 31, 2026 Business Wire

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

News Thumbnail
8:00 AM | Saturday | May 30, 2026 Business Wire

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

News Thumbnail
8:00 AM | Friday | May 29, 2026 Business Wire

Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

News Thumbnail
10:00 AM | Wednesday | May 27, 2026 Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

News Thumbnail
9:00 AM | Wednesday | May 20, 2026 Business Wire

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

News Thumbnail
5:05 AM | Wednesday | May 20, 2026 Business Wire

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

News Thumbnail
8:00 AM | Monday | May 18, 2026 PRNewsWire

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

News Thumbnail

Pfizer Announces Chief Financial Officer Transition

Business Wire

6:45 AM | Thursday | Jun 18, 2026

news photo
Loading...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that Dave Denton, Chief Financial Officer, will step down from his current role and leave the company on August 15 for a professional opportunity outside of the pharmaceutical industry in consumer goods, which he has accepted. The company has named Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, as Interim Chief Financial Officer, effective August 16, while Pfizer conducts a comprehens.

Read full article redirect
6:45 AM | Thursday | Jun 18, 2026

Pfizer Announces Chief Financial Officer Transition

Business Wire

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that Dave Denton, Chief Financial Officer, will step down from his current role and leave the company on August 15 for a professional opportunity outside of the pharmaceutical industry in consumer goods, which he has accepted. The company has named Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, as Interim Chief Financial Officer, effective August 16, while Pfizer conducts a comprehens.

Read full article arrow
NEW News Thumbnail
6:45 AM | Monday | Jun 8, 2026

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

Business Wire

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for HYMPAVZI® (marstacimab-hncq) to include the treatment of patients with hemophilia A or B 12 years and older with inhibitors and pediatric patients (ages 6 to 11 years) with or without inhibitors. HYMPAVZI is now indicated in the U.
S. for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patie.

Read full article arrow
News Thumbnail
9:00 AM | Saturday | Jun 6, 2026

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

Business Wire

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented detailed results from multiple Phase 2b studies of berobenatide (PF'3944), an investigational, potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, during a late-breaking expert symposium at the 86th Scientific Sessions of the American Diabetes Association (ADA). The objectives for the Phase 2 studies were to identify the right doses for Phase 3 and to test escalation schemes. Across both weekly and monthl.

Read full article arrow
News Thumbnail
10:00 AM | Monday | Jun 1, 2026

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Business Wire

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:00 a.m. EDT. To listen to the webcast, visit our web site at www.
pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today.
The transcri.

Read full article arrow
News Thumbnail
8:00 AM | Sunday | May 31, 2026

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

Business Wire

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) versus FOLFIRI with or without bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. These results will be.

Read full article arrow
News Thumbnail
8:00 AM | Saturday | May 30, 2026

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

Business Wire

NEW YORK--(BUSINESS WIRE)--TALAPRO-3 Data Presented at ASCO.

Read full article arrow
News Thumbnail
8:00 AM | Friday | May 29, 2026

Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

Business Wire

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial evaluating LORBRENA® (lorlatinib, a third-generation ALK inhibitor, available in Europe under the brand name LORVIQUA®) versus XALKORI® (crizotinib) in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC). At seven years, patients treated with LORBRENA had a 55% likelihood of re.

Read full article arrow
News Thumbnail
10:00 AM | Wednesday | May 27, 2026

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Business Wire

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 2:00 p.m. EDT. To view and listen to the webcast, visit our web site at www.
pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning to.

Read full article arrow
News Thumbnail
9:00 AM | Wednesday | May 20, 2026

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

Business Wire

NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, today announced a strategic collaboration with Pfizer Inc. to advance the development of Pfizer's oncology portfolio through a science‑driven and scaled research program designed to bring promising therapies to patients faster and closer to home. Central to the collaboration is SCRI's Accelero™, a next-generation clinic.

Read full article arrow
News Thumbnail
5:05 AM | Wednesday | May 20, 2026

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

Business Wire

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced data from its Phase 2 study (NCT06524414) evaluating the safety, tolerability and immunogenicity of a four-dose series of its investigational 25-valent pneumococcal conjugate vaccine candidate PF-07872412 (25vPnC) in infants compared to four doses of PREVNAR 20 at months 2, 4, 6 and 12-15. Based on the strong immune responses observed for all 25vPnC serotypes from Phase 2, compared to PREVNAR 20, Pfizer is confident that the req.

Read full article arrow
News Thumbnail
8:00 AM | Monday | May 18, 2026

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

PRNewsWire

10 abstracts, including two oral presentations, reinforce Astellas' long-term commitment to advancing oncology care TOKYO, May 18, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced it will present new data across its oncology portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 29 - June 2 in Chicago, reinforcing Astellas' sustained commitment to improving outcomes for people living with cancer. The data will provide further insight into the durable efficacy of established treatment approaches, their use in clinical practice, and ongoing areas of research and development.

Read full article arrow
News Thumbnail